Reply to T.J.A. Dekker
- PMID: 32658630
- DOI: 10.1200/JCO.20.01212
Reply to T.J.A. Dekker
Comment on
-
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.J Clin Oncol. 2020 Jun 10;38(17):1887-1896. doi: 10.1200/JCO.19.02318. Epub 2020 Feb 14. J Clin Oncol. 2020. PMID: 32058843 Free PMC article. Clinical Trial.
-
HER2-Targeted Therapies in HER2-Low-Expressing Breast Cancer.J Clin Oncol. 2020 Oct 1;38(28):3350-3351. doi: 10.1200/JCO.20.00657. Epub 2020 Jul 13. J Clin Oncol. 2020. PMID: 32658628 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical